Through the agreement 4SC and Crelux will implement a hit-finding program using 4SC’s in silico screening platform to identify candidate compounds that act synergistically with RNA molecules for cancer immunotherapy. Crelux will apply molecular biological tests for optimizing the compounds using its Intract-MS assays. Ribological will be responsible for carrying out further preclinical testing and potentially clinical trials to evaluate identified compounds in combination with its RNA-based drugs.

“This is the first major joint project that we have launched as part of our new strategic i2c (idea to candidate) cooperation with our partner Crelux,” remarks Daniel Vitt, MD at 4SC Discovery and CSO at parent company 4SC. “As service providers and cooperation partners for biotech and pharma companies, 4SC Discovery and Crelux together can cover both the entire value chain from the idea for a product to the preclinical drug development candidate.”

The i2C platform has been established to offer clients a seamless process from early concept through to preclinical development candidates ready for testing in animal models. Services are available through fee-based agreements, and also through risk-sharing collaborations.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.